Strides Pharma Science Ltd Technical Momentum Shifts Signal Bullish Outlook

Technical Trend Shift and Moving Averages

Recent analysis reveals that Strides Pharma’s technical trend has transitioned from mildly bullish to outright bullish, signalling a more robust upward momentum. The daily moving averages are firmly bullish, indicating that short-term price action is gaining strength. The stock’s current price of ₹1,102.75 is comfortably above its previous close of ₹1,083.15, with intraday highs reaching ₹1,122.50 and lows at ₹1,088.55, underscoring positive price momentum.

Moving averages often serve as critical support and resistance levels, and the bullish stance on daily averages suggests that the stock is likely to maintain its upward trajectory in the near term. This technical improvement aligns with the company’s small-cap market capitalisation status, which often experiences more pronounced price swings and momentum shifts.

MACD and Momentum Oscillators

The Moving Average Convergence Divergence (MACD) indicator presents a nuanced picture. On a weekly basis, the MACD remains mildly bearish, indicating some short-term caution among traders. However, the monthly MACD has turned bullish, signalling that the longer-term momentum is improving. This divergence between weekly and monthly MACD readings suggests that while short-term volatility may persist, the broader trend favours upward movement.

Complementing this, the Know Sure Thing (KST) oscillator is bullish on a weekly timeframe but mildly bearish monthly, reinforcing the mixed momentum signals. Such oscillators are valuable for timing entries and exits, and the current readings imply that investors should monitor weekly trends closely for confirmation of sustained strength.

RSI and Bollinger Bands Analysis

The Relative Strength Index (RSI) offers a more cautious outlook. On a weekly basis, the RSI is neutral, providing no clear signal of overbought or oversold conditions. However, the monthly RSI is bearish, suggesting some underlying weakness or potential for a pullback in the longer term. This divergence between weekly and monthly RSI readings highlights the importance of timeframe when interpreting momentum indicators.

Meanwhile, Bollinger Bands present a more optimistic scenario. The weekly Bollinger Bands are bullish, indicating that the stock price is trending towards the upper band, which often signals strong buying interest. The monthly Bollinger Bands are mildly bullish, reinforcing the notion that volatility is contained within an upward channel. This technical setup supports the view that Strides Pharma is experiencing a positive price momentum phase, albeit with some caution warranted over extended periods.

Volume and Dow Theory Signals

Volume-based indicators such as On-Balance Volume (OBV) show no clear trend on a weekly basis but are bullish monthly. This suggests that accumulation is occurring over the longer term, which is a positive sign for sustained price appreciation. The Dow Theory readings echo this mixed sentiment, with no discernible trend weekly but a bullish stance monthly, indicating that the broader market forces may be aligning favourably for the stock.

Comparative Performance Against Sensex

Strides Pharma’s price momentum is further validated by its impressive returns relative to the benchmark Sensex index. Year-to-date, the stock has delivered a 22.21% return compared to the Sensex’s negative 9.96%. Over the past year, Strides Pharma has outperformed with a 23.02% gain versus the Sensex’s decline of 8.72%. Even more striking is the three-year return of 434.82%, dwarfing the Sensex’s 20.05% gain, and a five-year return of 200.42% against the Sensex’s 46.01%. These figures underscore the stock’s strong relative performance and resilience in a challenging market environment.

Mojo Score Upgrade and Market Positioning

Reflecting these technical and fundamental improvements, MarketsMOJO has upgraded Strides Pharma’s Mojo Grade from Sell to Hold as of 6 April 2026, with a current Mojo Score of 63.0. This upgrade signals a shift in analyst sentiment, recognising the stock’s improved technical parameters and potential for further gains. The company remains classified as a small-cap within the Pharmaceuticals & Biotechnology sector, a segment known for its growth potential and volatility.

Investment Implications and Outlook

Investors analysing Strides Pharma Science Ltd should note the confluence of bullish signals from moving averages, monthly MACD, and Bollinger Bands, which collectively suggest a strengthening upward momentum. However, caution is advised given the mixed readings from weekly MACD, monthly RSI, and KST indicators, which highlight potential short-term volatility and the possibility of intermittent pullbacks.

The stock’s strong relative performance against the Sensex over multiple time horizons reinforces its appeal as a growth-oriented small-cap within the pharmaceuticals sector. The recent upgrade in Mojo Grade to Hold reflects a more balanced risk-reward profile, making it a viable candidate for investors seeking exposure to the sector’s innovation and growth potential while managing downside risks.

Given the technical momentum and fundamental backdrop, market participants should monitor weekly technical signals closely for confirmation of sustained bullishness. The stock’s proximity to its 52-week high of ₹1,231.45 suggests room for further appreciation, though profit-taking near resistance levels cannot be ruled out.

Conclusion

Strides Pharma Science Ltd is currently navigating a pivotal phase marked by improved technical momentum and a positive shift in analyst sentiment. While some indicators advise prudence, the overall technical landscape supports a bullish outlook, particularly over the medium to long term. Investors should weigh these factors carefully, considering both the opportunities and risks inherent in a small-cap pharmaceutical stock exhibiting mixed but improving momentum signals.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today